Compare RDIB & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | FOCL |
|---|---|---|
| Founded | 1937 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.2M | 206.3M |
| IPO Year | 1994 | 1998 |
| Metric | RDIB | FOCL |
|---|---|---|
| Price | $8.55 | $4.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.80 |
| AVG Volume (30 Days) | 2.3K | ★ 42.9K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $70,527,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | $34.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $8.00 | $3.97 |
| 52 Week High | $24.00 | $6.40 |
| Indicator | RDIB | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 52.06 |
| Support Level | $8.21 | $3.99 |
| Resistance Level | $10.22 | $4.49 |
| Average True Range (ATR) | 0.57 | 0.26 |
| MACD | -0.30 | 0.02 |
| Stochastic Oscillator | 30.49 | 64.72 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.